TALOPH(SH:600222) Xin Lang Cai Jing·2025-11-11 02:58Core Viewpoint - Tai Long Pharmaceutical experienced a 5.12% increase in stock price, reaching 7.18 CNY per share, with a trading volume of 1.29 billion CNY and a turnover rate of 3.21%, resulting in a total market capitalization of 4.121 billion CNY [1] Company Overview - Tai Long Pharmaceutical Co., Ltd. is located in Zhengzhou, Henan Province, and was established on August 31, 1998, with its listing date on November 5, 1999 [1] - The company operates in the pharmaceutical manufacturing industry, focusing on traditional Chinese medicine pieces, Chinese patent medicines, chemical drug manufacturing, and pharmaceutical wholesale, as well as preclinical research services [1] - The revenue composition of the company is as follows: 70.59% from drug manufacturing, 14.71% from drug research services, 14.42% from drug material circulation, and 0.28% from other sources [1] Shareholder Information - Among the top ten circulating shareholders of Tai Long Pharmaceutical, a fund under Huatai PineBridge holds a position. The Huatai Zhongzheng Traditional Chinese Medicine ETF (560080) entered the top ten circulating shareholders in the third quarter, holding 2.8616 million shares, which accounts for 0.5% of the circulating shares [2] - The Huatai Zhongzheng Traditional Chinese Medicine ETF (560080) was established on September 26, 2022, with a current scale of 2.489 billion CNY. Year-to-date, it has a return of 1.89%, ranking 4143 out of 4216 in its category; over the past year, it has incurred a loss of 5.38%, ranking 3855 out of 3922; since inception, it has achieved a return of 11.22% [2]